Hodgkin’s lymphoma can usually live for five years or even longer with aggressive treatment, and the five-year survival rate for Hodgkin’s lymphoma is around 90%. Hodgkin lymphoma is a kind of malignant tumor originated from lymph nodes or lymphatic tissues, which may be related to EBV infection, heredity, immune abnormality and other factors, and generally has a better prognosis. According to relevant statistics, the 5-year survival rate of Hodgkin’s lymphoma is around 90%, and the specific survival time needs to be decided according to the patient’s condition and treatment effect. The treatment of Hodgkin’s lymphoma is mainly based on chemotherapy, and can be treated with chemotherapeutic drugs such as doxorubicin, bleomycin, vincristine and dacarbazine, and with radiotherapy to promote its overall efficacy. Patients with Hodgkin’s lymphoma need to consult the hospital in time, and develop individualized treatment plans under the guidance of doctors according to tumor typing as well as staging, which can effectively prolong the survival of patients.